Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Receives Approval for Lisinopril and Lisinopril/HCTZ
Mylan Receives Approval for Lisinopril and Lisinopril/HCTZ PITTSBURGH, Jul 2, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Applications (ANDAs) for Lisinopril Tablets in 2.5 mg, 5
View HTML
Toggle Summary Mylan Receives Approval for Tramadol Hydrochloride Tablets
Mylan Receives Approval for Tramadol Hydrochloride Tablets PITTSBURGH, Jun 21, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg.
View HTML
Toggle Summary Mylan Declares Regular Quarterly Cash Dividend
Mylan Declares Regular Quarterly Cash Dividend PITTSBURGH--(BUSINESS WIRE)--June 17, 2002--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of four cents per share will be paid on July 15, 2002 to shareholders of record June 30, 2002.
View HTML
Toggle Summary Mylan Receives Approval on Levothyroxine Sodium Tablets
Mylan Receives Approval on Levothyroxine Sodium Tablets PITTSBURGH, Jun 11, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP, 0.025 mg, 0.05 mg,
View HTML
Toggle Summary Mylan Signs Licensing Agreement With 3M Pharmaceuticals
Mylan Signs Licensing Agreement With 3M Pharmaceuticals PITTSBURGH, Jun 7, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it has reached an agreement with 3M Pharmaceuticals for an exclusive supply and distribution agreement to sell Flecainide Acetate Tablets in
View HTML
Toggle Summary Mylan Laboratories Inc. Announces Share Repurchase Program
Mylan Laboratories Inc. Announces Share Repurchase Program PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the Board of Directors has authorized the Company to implement a Stock Repurchase Program pursuant to which the Company may repurchase up to
View HTML
Toggle Summary Wendy Cameron Elected to Mylan Laboratories' Board of Directors; Board is Increased to 11
Wendy Cameron Elected to Mylan Laboratories' Board of Directors; Board is Increased to 11 PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. announced today that it has named Wendy Cameron, 42, to its Board of Directors, effective May 2, 2002. Ms.
View HTML
Toggle Summary Mylan Reports Record Revenues and Earnings For The Fourth Quarter and Fiscal 2002
Mylan Reports Record Revenues and Earnings For The Fourth Quarter and Fiscal 2002 PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc.(NYSE: MYL) - Financial Highlights: - Net revenues increased 30% to exceed $1.1 billion for the fiscal year and 14% to $282.6 million for the quarter.
View HTML
Toggle Summary Mylan Establishes the Mylan Laboratories Charitable Foundation
Mylan Establishes the Mylan Laboratories Charitable Foundation PITTSBURGH, Pa., May 7, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that it has established the Mylan Laboratories Charitable Foundation, a 501 © (3) non-profit organization dedicated to providing support
View HTML
Toggle Summary Mylan Laboratories Inc. Announces Fiscal 2002 Fourth Quarter and Year End Earnings Release Date and Conference Call
Mylan Laboratories Inc. Announces Fiscal 2002 Fourth Quarter and Year End Earnings Release Date and Conference Call PITTSBURGH, Apr 30, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its fiscal 2002 fourth quarter and full year financial results
View HTML